PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
118.09%
Revenue growth at 50-75% of 4997.T's 187.52%. Martin Whitman would worry about competitiveness or product relevance.
134.81%
Gross profit growth at 50-75% of 4997.T's 211.74%. Martin Whitman would question if cost structure or brand is lagging.
2047.84%
EBIT growth 50-75% of 4997.T's 3475.52%. Martin Whitman would suspect suboptimal resource allocation.
810.34%
Operating income growth under 50% of 4997.T's 4776.04%. Michael Burry would be concerned about deeper cost or sales issues.
929.47%
Net income growth under 50% of 4997.T's 2114.12%. Michael Burry would suspect the firm is falling well behind a key competitor.
928.95%
EPS growth under 50% of 4997.T's 2110.65%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
928.95%
Diluted EPS growth under 50% of 4997.T's 2110.65%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.71%
10Y revenue/share CAGR at 50-75% of 4997.T's 70.94%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
56.91%
5Y revenue/share CAGR above 1.5x 4997.T's 11.91%. David Dodd would look for consistent product or market expansions fueling outperformance.
-35.67%
Negative 3Y CAGR while 4997.T stands at 25.71%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Negative 10Y OCF/share CAGR while 4997.T stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.14%
Net income/share CAGR at 75-90% of 4997.T's 60.47%. Bill Ackman would press for strategic moves to boost long-term earnings.
87.56%
Positive 5Y CAGR while 4997.T is negative. John Neff might view this as a strong mid-term relative advantage.
-9.54%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
294.34%
10Y equity/share CAGR above 1.5x 4997.T's 48.75%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
56.00%
Positive 5Y equity/share CAGR while 4997.T is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
14.07%
Positive short-term equity growth while 4997.T is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
46.41%
AR growth well above 4997.T's 55.48%. Michael Burry fears inflated revenue or higher default risk in the near future.
-31.45%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-5.08%
Negative asset growth while 4997.T invests at 5.76%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
11.77%
BV/share growth above 1.5x 4997.T's 1.79%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-15.10%
We’re deleveraging while 4997.T stands at 19.61%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-5.64%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-23.73%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.